Lipocine Inc. (LPCN) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
LPCN currently has 8.24M outstanding shares. with significant dilution risk as 159M authorized shares could dilute existing holders by 1934.5%. The company has significantly diluted shareholders by 53.76% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 8.2M shares outstanding |
8.2M | 160M |
| Nov 06, 2025 |
10-Q filing | 5.4M shares outstanding |
5.4M | 160M |
| Aug 05, 2025 |
10-Q filing | 5.4M shares outstanding |
5.4M | 160M |
| May 08, 2025 |
10-Q filing | 5.3M shares outstanding |
5.3M | 160M |
| Mar 13, 2025 |
10-K filing | 5.3M shares outstanding |
5.3M | 160M |
| Nov 07, 2024 |
10-Q filing | 5.3M shares outstanding |
5.3M | 160M |
| Aug 08, 2024 |
10-Q filing | 5.3M shares outstanding |
5.3M | 160M |
| May 09, 2024 |
10-Q filing | 5.4M shares outstanding |
5.4M | 160M |
| Apr 23, 2024 |
S-3/A filing: LIPOCINE INC. is offering up to $150,000,000 of any combination of Common Stock, Preferred Stock, Debt Securities, Warrants and Units. |
200M | 0 |
| Mar 07, 2024 |
10-K filing | 5.3M shares outstanding |
5.3M | 160M |
| Nov 22, 2023 |
S-3 filing: LIPOCINE INC. files an S-3 form to register the offering of Common Stock, Preferred Stock, Debt Securities, Warrants and Units, with a total value of up to $150,000,000. |
200M | 0 |
| Nov 08, 2023 |
10-Q filing | 5.3M shares outstanding |
5.3M | 160M |
| Aug 10, 2023 |
10-Q filing | 5.2M shares outstanding |
5.2M | 160M |
| May 11, 2023 |
10-Q filing | 88.5M shares outstanding |
89M | 79M |
| Mar 10, 2023 |
10-K filing | 88.5M shares outstanding |
88M | 79M |
| Mar 10, 2023 |
8-K filing: Lipocine Inc. amended its bylaws on March 7, 2023, to change the quorum requirement for stockholder meetings from a majority to one-third of outstanding shares. The board also declared a dividend of Series B Preferred Stock, with each share of common stock receiving one one-thousandth of a share of Series B Preferred Stock. This preferred stock grants voting rights specifically for matters related to a reverse stock split. |
89M | 79M |
| Nov 09, 2022 |
10-Q filing | 88.5M shares outstanding |
89M | 79M |
| Aug 08, 2022 |
10-Q filing | 88.5M shares outstanding |
88M | 79M |
| May 09, 2022 |
10-Q filing | 88.3M shares outstanding |
88M | 79M |
| Mar 09, 2022 |
10-K filing | 86.9M shares outstanding |
87M | 81M |
| Nov 10, 2021 |
10-Q filing | 88.3M shares outstanding |
88M | 79M |
| Aug 05, 2021 |
10-Q filing | 88.3M shares outstanding |
88M | 79M |
| May 06, 2021 |
10-Q filing | 88.3M shares outstanding |
88M | 79M |
| Mar 11, 2021 |
10-K filing | 88.3M shares outstanding |
88M | 79M |
| Jan 27, 2021 |
8-K filing: Lipocine Inc. entered into an Underwriting Agreement to issue and sell 14,285,714 shares of common stock at $1.75 per share, expecting to receive approximately $23.3 million in net proceeds. ($25.0M proceeds) |
66M | 100M |
| Nov 13, 2020 |
S-3 filing: LIPOCINE INC. is offering common stock, preferred stock, debt securities, warrants and units for a total of $150,000,000. |
66M | 100M |
| Nov 10, 2020 |
10-Q filing | 65.7M shares outstanding |
66M | 0 |
| Aug 24, 2020 |
8-K filing: Lipocine Inc. may issue and sell shares of its common stock from time to time through Cantor Fitzgerald, with the potential to sell an additional $50,000,000 of shares after the date of the filing. |
66M | 0 |
| Aug 06, 2020 |
10-Q filing | 65.6M shares outstanding |
66M | 0 |
| May 07, 2020 |
10-Q filing | 47.9M shares outstanding |
48M | 0 |
| Mar 13, 2020 |
10-K filing | 47.9M shares outstanding |
48M | 0 |
| Feb 26, 2020 |
8-K filing: Lipocine Inc. entered into a placement agency agreement with Roth Capital Partners, LLC to arrange the sale of 10,084,034 Class A Units, each consisting of one share of common stock and one warrant, at an offering price of $0.595 per Class A Unit, for gross proceeds of approximately $6 million. ($12.0M proceeds) |
N/A | 0 |